Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8485828 | Vaccine | 2018 | 7 Pages |
Abstract
Overall, the impact of PCV10 vaccination on IPD was high in vaccine-eligible children, with a major reduction in vaccine-type disease, and without notable replacement by other serotype groups. Our data suggest that PCV10 results in long-lasting direct cross-protection against 6A IPD. For 19A, no net reduction was observed six years after NVP introduction in the vaccine-eligible cohort. The indirect impact on IPD in unvaccinated children sustained.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Hanna Rinta-Kokko, Arto A. Palmu, Kari Auranen, J. Pekka Nuorti, Maija Toropainen, Lotta Siira, Mikko J. Virtanen, Hanna Nohynek, Jukka Jokinen,